Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Stock Competitors & Peer Comparison
See PTGX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PTGX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PTGX | $143.81 | -2.95% | 9.5B | 143.48 | $1.03 | N/A |
| VRTX | $514.50 | -0.18% | 131.9B | 27.31 | $19.03 | N/A |
| REGN | $776.95 | -0.58% | 81.8B | 17.40 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $983.59 | -0.08% | 61.6B | 89.40 | $11.08 | N/A |
| MRNA | $142.97 | -0.69% | 58.2B | -18.00 | -$8.15 | N/A |
| RVMDW | $11.27 | -0.18% | 44.5B | -1.29 | -$8.82 | N/A |
| RVMD | $203.39 | -0.19% | 43.6B | -23.26 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $348.73 | +0.64% | 37.8B | 62.29 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PTGX vs VRTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, VRTX has a market cap of 131.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while VRTX trades at $514.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas VRTX's P/E ratio is 27.31. In terms of profitability, PTGX's ROE is +0.12%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, PTGX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PTGX vs REGN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, REGN has a market cap of 81.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while REGN trades at $776.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas REGN's P/E ratio is 17.40. In terms of profitability, PTGX's ROE is +0.12%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PTGX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
PTGX vs VRNA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PTGX's ROE is +0.12%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, PTGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
PTGX vs ARGX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ARGX trades at $983.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ARGX's P/E ratio is 89.40. In terms of profitability, PTGX's ROE is +0.12%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, PTGX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
PTGX vs MRNA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MRNA has a market cap of 58.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MRNA trades at $142.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MRNA's P/E ratio is -18.00. In terms of profitability, PTGX's ROE is +0.12%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, PTGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PTGX vs RVMDW Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RVMDW has a market cap of 44.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RVMDW trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, PTGX's ROE is +0.12%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, PTGX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PTGX vs RVMD Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RVMD trades at $203.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RVMD's P/E ratio is -23.26. In terms of profitability, PTGX's ROE is +0.12%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, PTGX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
PTGX vs SGEN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PTGX's ROE is +0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PTGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
PTGX vs ONC Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ONC has a market cap of 37.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ONC trades at $348.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ONC's P/E ratio is 62.29. In terms of profitability, PTGX's ROE is +0.12%, compared to ONC's ROE of +0.14%. Regarding short-term risk, PTGX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PTGX vs ALNY Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ALNY has a market cap of 33.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ALNY trades at $241.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ALNY's P/E ratio is 45.04. In terms of profitability, PTGX's ROE is +0.12%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, PTGX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PTGX vs ROIV Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ROIV has a market cap of 29.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ROIV trades at $39.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ROIV's P/E ratio is -39.02. In terms of profitability, PTGX's ROE is +0.12%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, PTGX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
PTGX vs INSM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, INSM has a market cap of 27.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while INSM trades at $119.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas INSM's P/E ratio is -30.49. In terms of profitability, PTGX's ROE is +0.12%, compared to INSM's ROE of -1.11%. Regarding short-term risk, PTGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
PTGX vs BNTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BNTX trades at $97.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BNTX's P/E ratio is -12.82. In terms of profitability, PTGX's ROE is +0.12%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, PTGX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
PTGX vs INCY Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, INCY has a market cap of 24.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while INCY trades at $121.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas INCY's P/E ratio is 16.42. In terms of profitability, PTGX's ROE is +0.12%, compared to INCY's ROE of +0.30%. Regarding short-term risk, PTGX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PTGX vs UTHR Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, UTHR has a market cap of 21.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while UTHR trades at $501.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas UTHR's P/E ratio is 17.99. In terms of profitability, PTGX's ROE is +0.12%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, PTGX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PTGX vs BGNE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PTGX's ROE is +0.12%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, PTGX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
PTGX vs GMAB Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, GMAB has a market cap of 20B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while GMAB trades at $34.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas GMAB's P/E ratio is 24.60. In terms of profitability, PTGX's ROE is +0.12%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, PTGX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PTGX vs DNA-WT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PTGX's ROE is +0.12%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, PTGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PTGX vs ASND Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ASND trades at $235.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ASND's P/E ratio is -109.47. In terms of profitability, PTGX's ROE is +0.12%, compared to ASND's ROE of +1.90%. Regarding short-term risk, PTGX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PTGX vs NBIX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, NBIX has a market cap of 15.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while NBIX trades at $149.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas NBIX's P/E ratio is 22.72. In terms of profitability, PTGX's ROE is +0.12%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, PTGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PTGX vs JAZZ Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while JAZZ trades at $240.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas JAZZ's P/E ratio is 9.17. In terms of profitability, PTGX's ROE is +0.12%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, PTGX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check JAZZ's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PTGX vs SMMT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while SMMT trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas SMMT's P/E ratio is -16.45. In terms of profitability, PTGX's ROE is +0.12%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PTGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PTGX vs BBIO Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BBIO trades at $68.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BBIO's P/E ratio is -19.35. In terms of profitability, PTGX's ROE is +0.12%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, PTGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PTGX vs EXEL Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while EXEL trades at $56.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas EXEL's P/E ratio is 16.06. In terms of profitability, PTGX's ROE is +0.12%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, PTGX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PTGX vs BMRN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BMRN trades at $64.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BMRN's P/E ratio is 31.93. In terms of profitability, PTGX's ROE is +0.12%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, PTGX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PTGX vs HALO Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while HALO trades at $106.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas HALO's P/E ratio is 20.14. In terms of profitability, PTGX's ROE is +0.12%, compared to HALO's ROE of +1.81%. Regarding short-term risk, PTGX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PTGX vs KRTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PTGX's ROE is +0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PTGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PTGX vs MDGL Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MDGL trades at $518.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MDGL's P/E ratio is -42.19. In terms of profitability, PTGX's ROE is +0.12%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, PTGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PTGX vs ARWR Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ARWR has a market cap of 11.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ARWR trades at $72.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ARWR's P/E ratio is -35.85. In terms of profitability, PTGX's ROE is +0.12%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, PTGX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PTGX vs TECH Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TECH trades at $72.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TECH's P/E ratio is 37.25. In terms of profitability, PTGX's ROE is +0.12%, compared to TECH's ROE of +0.09%. Regarding short-term risk, PTGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PTGX vs RNAM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PTGX's ROE is +0.12%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PTGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PTGX vs AXSM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while AXSM trades at $208.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas AXSM's P/E ratio is -56.55. In terms of profitability, PTGX's ROE is +0.12%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, PTGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PTGX vs KRYS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while KRYS trades at $335.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas KRYS's P/E ratio is 42.61. In terms of profitability, PTGX's ROE is +0.12%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PTGX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PTGX vs RXDX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PTGX's ROE is +0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PTGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RXDX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PTGX vs KYMR Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while KYMR trades at $113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas KYMR's P/E ratio is -35.82. In terms of profitability, PTGX's ROE is +0.12%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, PTGX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PTGX vs PRAX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while PRAX trades at $315.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas PRAX's P/E ratio is -25.58. In terms of profitability, PTGX's ROE is +0.12%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, PTGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PTGX vs NUVL Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PTGX's ROE is +0.12%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PTGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PTGX vs CYTK Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CYTK trades at $69.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CYTK's P/E ratio is -10.03. In terms of profitability, PTGX's ROE is +0.12%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, PTGX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PTGX vs CRNX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CRNX's P/E ratio is -16.86. In terms of profitability, PTGX's ROE is +0.12%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PTGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CRNX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
PTGX vs TXG Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TXG has a market cap of 8.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TXG trades at $74.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TXG's P/E ratio is -118.83. In terms of profitability, PTGX's ROE is +0.12%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PTGX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PTGX vs IBRX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while IBRX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas IBRX's P/E ratio is -8.63. In terms of profitability, PTGX's ROE is +0.12%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, PTGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PTGX vs IMGN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PTGX's ROE is +0.12%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PTGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PTGX vs PCVX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while PCVX trades at $58.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas PCVX's P/E ratio is -7.80. In terms of profitability, PTGX's ROE is +0.12%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, PTGX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check PCVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PTGX vs IONS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, IONS has a market cap of 8.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while IONS trades at $47.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas IONS's P/E ratio is -29.91. In terms of profitability, PTGX's ROE is +0.12%, compared to IONS's ROE of -1.11%. Regarding short-term risk, PTGX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check IONS's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
PTGX vs TWST Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TWST has a market cap of 8.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TWST trades at $136.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TWST's P/E ratio is -60.70. In terms of profitability, PTGX's ROE is +0.12%, compared to TWST's ROE of -0.30%. Regarding short-term risk, PTGX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TWST's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PTGX vs BPMC Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PTGX's ROE is +0.12%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PTGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PTGX vs APGE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas APGE's P/E ratio is -31.19. In terms of profitability, PTGX's ROE is +0.12%, compared to APGE's ROE of -0.30%. Regarding short-term risk, PTGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check APGE's competition here
Abivax S.A. (NASDAQ: ABVX)
PTGX vs ABVX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ABVX trades at $107.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ABVX's P/E ratio is -59.54. In terms of profitability, PTGX's ROE is +0.12%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PTGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ABVX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PTGX vs TGTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TGTX trades at $53.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TGTX's P/E ratio is 19.57. In terms of profitability, PTGX's ROE is +0.12%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, PTGX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PTGX vs CERE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CERE's P/E ratio is -16.47. In terms of profitability, PTGX's ROE is +0.12%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PTGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PTGX vs SYRE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while SYRE trades at $89.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas SYRE's P/E ratio is -46.56. In terms of profitability, PTGX's ROE is +0.12%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, PTGX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PTGX vs IMVT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, IMVT has a market cap of 7.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while IMVT trades at $36.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas IMVT's P/E ratio is -13.35. In terms of profitability, PTGX's ROE is +0.12%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, PTGX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
PTGX vs MTSR Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PTGX's ROE is +0.12%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PTGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PTGX vs CAI Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CAI trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CAI's P/E ratio is 73.19. In terms of profitability, PTGX's ROE is +0.12%, compared to CAI's ROE of +0.19%. Regarding short-term risk, PTGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PTGX vs RYTM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RYTM trades at $97.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RYTM's P/E ratio is -32.94. In terms of profitability, PTGX's ROE is +0.12%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, PTGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PTGX vs BLTE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while BLTE trades at $169.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas BLTE's P/E ratio is -92.51. In terms of profitability, PTGX's ROE is +0.12%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, PTGX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
PTGX vs MRUS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PTGX's ROE is +0.12%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PTGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PTGX vs ACLX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PTGX's ROE is +0.12%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PTGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PTGX vs RETA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RETA's P/E ratio is -66.29. In terms of profitability, PTGX's ROE is +0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PTGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
PTGX vs CGON Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CGON trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CGON's P/E ratio is -27.43. In terms of profitability, PTGX's ROE is +0.12%, compared to CGON's ROE of -0.25%. Regarding short-term risk, PTGX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PTGX vs CNTA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PTGX's ROE is +0.12%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PTGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CNTA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PTGX vs SRRK Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, SRRK has a market cap of 6.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while SRRK trades at $48.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas SRRK's P/E ratio is -15.03. In terms of profitability, PTGX's ROE is +0.12%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, PTGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check SRRK's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PTGX vs TVTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TVTX trades at $61.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TVTX's P/E ratio is -146.20. In terms of profitability, PTGX's ROE is +0.12%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, PTGX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PTGX vs DNTH Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while DNTH trades at $104.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas DNTH's P/E ratio is -25.95. In terms of profitability, PTGX's ROE is +0.12%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, PTGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DNTH's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PTGX vs MIRM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MIRM trades at $93.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MIRM's P/E ratio is -6.65. In terms of profitability, PTGX's ROE is +0.12%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, PTGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check MIRM's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
PTGX vs ORKA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ORKA has a market cap of 5.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ORKA trades at $90.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ORKA's P/E ratio is -49.48. In terms of profitability, PTGX's ROE is +0.12%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, PTGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ORKA's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PTGX vs COGT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while COGT trades at $32.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas COGT's P/E ratio is -15.83. In terms of profitability, PTGX's ROE is +0.12%, compared to COGT's ROE of -0.73%. Regarding short-term risk, PTGX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check COGT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PTGX vs XENE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, XENE has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while XENE trades at $56.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas XENE's P/E ratio is -12.38. In terms of profitability, PTGX's ROE is +0.12%, compared to XENE's ROE of -0.44%. Regarding short-term risk, PTGX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PTGX vs LGND Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while LGND trades at $271.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas LGND's P/E ratio is 30.81. In terms of profitability, PTGX's ROE is +0.12%, compared to LGND's ROE of +0.20%. Regarding short-term risk, PTGX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PTGX vs CDTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PTGX's ROE is +0.12%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, PTGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CDTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
PTGX vs ERAS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ERAS trades at $15.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ERAS's P/E ratio is -17.38. In terms of profitability, PTGX's ROE is +0.12%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, PTGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PTGX vs PTCT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while PTCT trades at $65.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas PTCT's P/E ratio is -28.53. In terms of profitability, PTGX's ROE is +0.12%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, PTGX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check PTCT's competition here
Abcam plc (NASDAQ: ABCM)
PTGX vs ABCM Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PTGX's ROE is +0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PTGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PTGX vs ISEE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PTGX's ROE is +0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PTGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ISEE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PTGX vs DFTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, DFTX has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while DFTX trades at $36.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas DFTX's P/E ratio is N/A. In terms of profitability, PTGX's ROE is +0.12%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, PTGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check DFTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PTGX vs APLS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas APLS's P/E ratio is 38.35. In terms of profitability, PTGX's ROE is +0.12%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PTGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PTGX vs CRSP Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CRSP trades at $51.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CRSP's P/E ratio is -11.13. In terms of profitability, PTGX's ROE is +0.12%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, PTGX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PTGX vs EWTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while EWTX trades at $43.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas EWTX's P/E ratio is -24.12. In terms of profitability, PTGX's ROE is +0.12%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, PTGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PTGX vs TERN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TERN's P/E ratio is -51.41. In terms of profitability, PTGX's ROE is +0.12%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PTGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
PTGX vs ACAD Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ACAD trades at $26.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ACAD's P/E ratio is 12.40. In terms of profitability, PTGX's ROE is +0.12%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, PTGX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PTGX vs FOLD Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PTGX's ROE is +0.12%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PTGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PTGX vs AKRO Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PTGX's ROE is +0.12%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PTGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PTGX vs ALPN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PTGX's ROE is +0.12%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PTGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
PTGX vs MANE Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MANE trades at $102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MANE's P/E ratio is -32.36. In terms of profitability, PTGX's ROE is +0.12%, compared to MANE's ROE of -0.38%. Regarding short-term risk, PTGX is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
PTGX vs OPT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas OPT's P/E ratio is -1.52. In terms of profitability, PTGX's ROE is +0.12%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PTGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
PTGX vs PRTC Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas PRTC's P/E ratio is -3.78. In terms of profitability, PTGX's ROE is +0.12%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, PTGX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check PRTC's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
PTGX vs PBLS Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, PBLS has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while PBLS trades at $35.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas PBLS's P/E ratio is -41.09. In terms of profitability, PTGX's ROE is +0.12%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, PTGX is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check PBLS's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
PTGX vs RLAY Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RLAY trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RLAY's P/E ratio is -12.14. In terms of profitability, PTGX's ROE is +0.12%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, PTGX is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RLAY's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
PTGX vs IOVA Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, IOVA has a market cap of 4.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while IOVA trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas IOVA's P/E ratio is -12.68. In terms of profitability, PTGX's ROE is +0.12%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, PTGX is similarly volatile compared to IOVA. This indicates similar risk in terms of short-term price fluctuations for PTGX.Check IOVA's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PTGX vs MRTX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PTGX's ROE is +0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PTGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
PTGX vs CELC Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CELC trades at $81.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CELC's P/E ratio is -19.43. In terms of profitability, PTGX's ROE is +0.12%, compared to CELC's ROE of -3.51%. Regarding short-term risk, PTGX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CELC's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
PTGX vs TNGX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TNGX trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TNGX's P/E ratio is -29.57. In terms of profitability, PTGX's ROE is +0.12%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, PTGX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
PTGX vs TLX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while TLX trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas TLX's P/E ratio is 122.96. In terms of profitability, PTGX's ROE is +0.12%, compared to TLX's ROE of +0.07%. Regarding short-term risk, PTGX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PTGX vs ADPT Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ADPT trades at $26.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ADPT's P/E ratio is -60.44. In terms of profitability, PTGX's ROE is +0.12%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, PTGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PTGX.Check ADPT's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
PTGX vs ELVN Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while ELVN trades at $53.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas ELVN's P/E ratio is -32.59. In terms of profitability, PTGX's ROE is +0.12%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, PTGX is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PTGX vs CPRX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CPRX's P/E ratio is 12.30. In terms of profitability, PTGX's ROE is +0.12%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PTGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PTGX vs RYZB Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PTGX's ROE is +0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PTGX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check RYZB's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
PTGX vs AMLX Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while AMLX trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas AMLX's P/E ratio is -22.43. In terms of profitability, PTGX's ROE is +0.12%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, PTGX is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check AMLX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PTGX vs CBAY Comparison September 2026
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTGX stands at 9.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PTGX is priced at $143.81 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTGX currently has a P/E ratio of 143.48, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PTGX's ROE is +0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PTGX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PTGX.Check CBAY's competition here